RET and non-small cell lung carcinoma: The latest version of the National Comprehensive Cancer Network Guidelines for NSCLC has recommended a few evidence-based predictive biomarkers for adenocarcinomas, large cell carcinomas, and NSCLC-NOS, in particular EGFR mutations, ALK rearrangements, ROS1 rearrangements, BRAF V600E mutation, KRAS mutations, NTRK 1/2/3 gene fusion, METex14 skipping mutations, RET rearrangements, and PD-L1 expression.